Bloomberg Anywhere Remote Login Bloomberg Terminal Request a Demo

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $2.29 USD
Change Today +0.03 / 1.33%
Volume 39.4K
CPXX On Other Exchanges
Symbol
Exchange
NASDAQ CM
Stuttgart
As of 1:38 PM 09/4/15 All times are local (Market data is delayed by at least 15 minutes).

celator pharmaceuticals inc (CPXX) Snapshot

Open
$2.23
Previous Close
$2.26
Day High
$2.31
Day Low
$2.23
52 Week High
01/12/15 - $3.53
52 Week Low
11/28/14 - $1.58
Market Cap
77.4M
Average Volume 10 Days
181.5K
EPS TTM
$-0.57
Shares Outstanding
33.8M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for CELATOR PHARMACEUTICALS INC (CPXX)

Related News

No related news articles were found.

celator pharmaceuticals inc (CPXX) Related Businessweek News

No Related Businessweek News Found

celator pharmaceuticals inc (CPXX) Details

Celator Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops therapies to treat cancer. Its proprietary drug ratio technology platform, CombiPlex, enables the rational design and rapid evaluation of optimized combinations incorporating traditional chemotherapies, as well as molecularly targeted agents to deliver enhanced anti-cancer activity. The company’s product pipeline includes CPX-351, a liposomal formulation of cytarabine:daunorubicin, which is in Phase III study for the treatment of acute myeloid leukemia; and CPX-1, a liposomal formulation of irinotecan:floxuridine that has completed Phase II study for the treatment of colorectal cancer. Its preclinical stage product candidate is CPX-8, a hydrophobic docetaxel prodrug nanoparticle formulation for vitro and vivo studies. The company was founded in 1999 and is headquartered in Ewing, New Jersey.

25 Employees
Last Reported Date: 03/17/15
Founded in 1999

celator pharmaceuticals inc (CPXX) Top Compensated Officers

Chief Executive Officer and Director
Total Annual Compensation: $530.3K
Founder, President and Chief Scientific Offic...
Total Annual Compensation: $343.2K
Chief Financial Officer and Vice President
Total Annual Compensation: $354.5K
Compensation as of Fiscal Year 2014.

celator pharmaceuticals inc (CPXX) Key Developments

Celator Pharmaceuticals, Inc. Appoints Michael R. Dougherty as Executive Chairman of Board of Directors

Celator Pharmaceuticals, Inc. announced the appointment of Michael R. Dougherty as Executive Chairman of its Board of Directors. Mr. Dougherty has been a director of Celator since July 2013 and has served as Chairman since September 2014. More recently, Mr. Dougherty has served as Chief Executive Officer of Kalidex Pharmaceuticals, Inc. and as President and Chief Executive Officer of Adolor Corporation. Mr. Dougherty currently serves on the Board of Directors of Cempra, Inc., Trevena, Inc. and Biota Pharmaceuticals, Inc. and previously served on the Board of Directors of ViroPharma Incorporated from January 2004 to January 2014.

Celator Pharmaceuticals, Inc. Reports Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2015

Celator Pharmaceuticals, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2015. For the quarter, operating loss was $4,481,313 against $4,577,822 a year ago. Interest and miscellaneous income was $3,111 against $1,942 a year ago. Net loss was $4,981,526 against $4,791,194 a year ago. Net loss per share basic and diluted was $0.15 against $0.18 a year ago. For the six months, operating loss was $8,863,954 against $8,845,930 a year ago. Interest and miscellaneous income was $6,252 against $4,257 a year ago. Net loss was $9,692,509 against $9,068,695 a year ago. Net loss per share basic and diluted was $0.29 against $0.35 a year ago.

Celator Pharmaceuticals, Inc. to Report Q2, 2015 Results on Aug 11, 2015

Celator Pharmaceuticals, Inc. announced that they will report Q2, 2015 results at 8:01 PM, GMT Standard Time on Aug 11, 2015

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
CPXX:US $2.29 USD +0.03

CPXX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for CPXX.
View Industry Companies
 

Industry Analysis

CPXX

Industry Average

Valuation CPXX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 5.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact CELATOR PHARMACEUTICALS INC, please visit www.celatorpharma.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.